Chemomab Therapeutics (2QV) Ratios
Chemomab Therapeutics Ratios
DE:2QV's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, DE:2QV's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 |
| Quick Ratio | 9.08 | 4.98 | 4.32 | 6.18 | 24.16 |
| Cash Ratio | 5.12 | 1.89 | 1.92 | 2.00 | 5.54 |
| Solvency Ratio | -6.04 | -4.05 | -4.69 | -4.03 | -4.31 |
| Operating Cash Flow Ratio | -7.59 | -4.80 | -4.87 | -3.01 | -4.67 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -134.43 | -309.87 | 0.00 | -116.82 |
| Net Current Asset Value | $ 11.95M | $ 12.61M | $ 15.74M | $ 34.90M | $ 59.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.02 | 0.02 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.25 | 1.30 | 1.19 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | -121.37 | -334.11 | -79.15 | -56.81 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -80.83 | -111.34 |
| Debt to Market Cap | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.07 | 0.13 | 0.20 | 0.18 |
| Net Debt to EBITDA | 0.80 | 0.41 | 0.35 | 0.47 | 1.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 98.11% | 100.00% |
| EBT Per EBIT | 94.02% | 94.61% | 95.14% | 98.76% | 100.90% |
| Return on Assets (ROA) | -65.13% | -82.20% | -109.34% | -64.20% | -19.39% |
| Return on Equity (ROE) | -72.93% | -103.01% | -142.50% | -76.32% | -20.30% |
| Return on Capital Employed (ROCE) | -77.57% | -107.22% | -147.05% | -78.57% | -20.04% |
| Return on Invested Capital (ROIC) | -77.57% | -105.46% | -145.77% | -76.82% | -19.97% |
| Return on Tangible Assets | -65.13% | -82.24% | -109.38% | -64.20% | -19.39% |
| Earnings Yield | -85.48% | -42.92% | -404.19% | -75.92% | -17.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.08 | 0.13 | 0.03 | 0.03 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4564.98 | -2818.32 | -10664.50 | -28794.25 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | -14461.60 |
| Days of Payables Outstanding | 0.00 | 4564.98 | 2818.32 | 10664.50 | 14332.66 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | -14461.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.76 | -3.44 | -8.02 | -7.13 | -4.77 |
| Free Cash Flow Per Share | -1.76 | -3.44 | -8.02 | -7.16 | -4.87 |
| Dividend Paid and CapEx Coverage Ratio | -3707.30 | -3114772.51 | -7873.67 | -299.57 | -51.77 |
| Capital Expenditure Coverage Ratio | -3707.30 | -3114772.51 | -7873.67 | -299.57 | -51.77 |
| Operating Cash Flow Coverage Ratio | 0.00 | -47.71 | -60.08 | -94.81 | -36.10 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -106.63% | -47.58% | -393.05% | -55.91% | -17.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.16 | -2.33 | -0.25 | -1.32 | -5.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.85 | 2.40 | 0.35 | 1.01 | 1.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.94 | -2.10 | -0.25 | -1.79 | -5.67 |
| Price-to-Operating Cash Flow Ratio | -0.94 | -2.10 | -0.25 | -1.79 | -5.78 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.04 | 0.02 | -0.01 | 0.07 |
| Enterprise Value Multiple | -0.31 | -1.92 | 0.11 | -0.81 | -4.64 |
| Enterprise Value | 2.96M | 26.75M | -2.91M | 23.11M | 57.23M |
| EV to EBITDA | -0.31 | -1.92 | 0.11 | -0.81 | -4.64 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.26 | -1.73 | 0.12 | -1.14 | -4.53 |
| EV to Operating Cash Flow | -0.26 | -1.73 | 0.12 | -1.14 | -4.62 |
| Tangible Book Value Per Share | 1.93 | 3.01 | 5.78 | 12.73 | 23.70 |
| Shareholders’ Equity Per Share | 1.93 | 3.02 | 5.79 | 12.73 | 23.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.41 | -3.11 | -8.25 | -9.72 | -4.81 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.00 |
| Interest Burden | 0.94 | 1.00 | 0.95 | 0.99 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.24 | 1.10 | 0.97 | 0.74 | 0.99 |
Currency in USD
